Xiaohu Zhang

8PUBLICATIONS
124CO-AUTHORS
Molecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Nov 05, 2026
Combination Therapy with AKT and MEK Inhibitors is Effective in Patient-Derived Models of Adrenocortical Carcinoma.

|Feb 11, 2026
Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma.

Patience Odeniyide, Alyza Skaist, Elizabeth Fenner

|Jul 24, 2025
Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC Models.

Benjamin C Brim, Andres F Leon, Erica L Beatson

|Jan 09, 2025
Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models.

Sara Ortega-Bertran, Juana Fernández-Rodríguez, Miriam Magallón-Lorenz

|Oct 14, 2024
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the Novel NAMPT Inhibitor OT-82.

Susana S Najera, Christopher J Ricketts, Laura S Schmidt

|Mar 07, 2024
Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts.

Yasuhiro Arakawa, Ukhyun Jo, Suresh Kumar

Pageof 2

Frequent Collaborators

7 joint publications

Craig Thomas

4 joint publications

Michele Ceribelli

4 joint publications

Kelli Wilson

4 joint publications

Carleen Klumpp-Thomas